Amgen and UCB re-file Evenity for US approvalAmgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that Share XAmgen and UCB re-file Evenity for US approvalhttps://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/
